NCT05154734View on ClinicalTrials.gov

Efficacy and Safety of Belimumab in Neuromyelitis Optica Spectrum Disorders

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

December 12, 2021

Primary Completion Date

June 30, 2023

Study Completion Date

April 9, 2024

Conditions
NMO Spectrum Disorder
Interventions
DRUG

Belimumab

Belimumab will be intravenously administered with a dose of 10mg/kg on Days 0,14 and28, then every 28 days until week 48, with a final evaluation at week 52.

Trial Locations (1)

300052

Tianjin Medical University General Hospital, Tianjin

All Listed Sponsors
collaborator

Tang-Du Hospital

OTHER

lead

Tianjin Medical University General Hospital

OTHER

NCT05154734 - Efficacy and Safety of Belimumab in Neuromyelitis Optica Spectrum Disorders | Biotech Hunter | Biotech Hunter